5428-41-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Cyanouracil is used as an anticancer agent for its ability to inhibit the growth of cancer cells. It is particularly effective in targeting various types of cancer, offering a potential therapeutic option for patients.
Used in Chemical Synthesis:
5-Cyanouracil is used as a synthetic intermediate in the production of pharmaceuticals, contributing to the development of new and innovative medications.
Used in Agricultural Chemicals:
5-Cyanouracil is utilized in the synthesis of agricultural chemicals, potentially enhancing crop protection and yield.
Used in Specialty Polymers:
5-Cyanouracil is used as a precursor in the synthesis of specialty polymers, which have unique properties and applications in various industries, including materials science and engineering.
Used in Chemical Compound Production:
As a precursor, 5-Cyanouracil is essential in the production of other chemical compounds, expanding its utility and impact across multiple chemical and industrial sectors.

InChI:InChI=1/C5H3N3O2/c6-1-3-2-7-5(10)8-4(3)9/h2H,(H2,7,8,9,10)

Upstream product

• 1187-34-4 α-Cyano-β-ethoxy-N-(ethoxycarbonyl)acrylamide 
• 85690-57-9 methyl (E)-2-cyano-3-ureido-2-propenoate 
• 162129-62-6 ethyl (E)-2-cyano-3-ureido-2-propenoate 
• 1187-34-4 α-cyano-β-ethoxy-N-ethoxycarbonylacrylamide 
• 16462-28-5 5-cyanocytosine 

Downstream Products

• 65906-82-3 5-cyano-6-ethoxy-5-fluoro-5,6-dihydrouracil 

Relevant academic research and scientific papers

A microwave-assisted high-efficient synthetic 5-cyanogenetic uracil method

The invention relates to a microwave-assisted high-efficiency method for synthesizing 5-cyanouracil, which comprises the following steps: carrying out microwave radiation on urea, malononitrile and triethyl orthoformate at the microwave reaction temperature of 60-80 DEG C under the microwave power of 500W under atmospheric pressure for 8-20 minutes, and filtering the residual triethyl orthoformate out of the reaction system to obtain a dicyan intermediate I; dissolving the obtained solid in a sodium ethylate 1.0-2.0 mol/L solution, carrying out radiation reaction at the microwave reaction temperature of 30-50 DEG C under the microwave power of 300W under atmospheric pressure for 30-50 minutes, adding activated carbon for decolorization, filtering, and acidifying the filtered precipitate with glacial acetic acid to obtain an intermediate II; and adding 2.5-3.0 mol/L dilute hydrochloric acid into the intermediate II, carrying out radiation at the microwave reaction temperature of 80-100 DEG C under the microwave power of 500W under atmospheric pressure for 30-50 minutes, cooling, and filtering to obtain the 5-cyanouracil.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Uracil reductase inactivators

The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).

5-Fluorouracil derivatives

Novel compounds comprising 5-fluorouracil or 5-fluorouridine covalently linked to 5-ethynyluracil, 5-ethynyluridine or 5-propynyluracil and pharmaceutical compositions comprising such compounds are disclosed.

Pharmaceutical compositions of 5-substituted uracil compounds

Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.

CYCLIZATION DICHOTOMY OF ESTERS OF 3-UREIDO-2-CYANO-2-PROPENOIC AND 3-UREIDO-2-ACYL-2-PROPENOIC ACIDS

The preparation of E and Z isomers of 3-ureido-2-cyano-2-propenoates Ia-Id and their base-catalyzed isomerization and cyclization to 5-carboxycytosine derivatives IIa-IIf and 5-cyanouracil derivatives IIIa and IIIb is described.Also described is the preparation of 3-ureido-2-acyl-2-propenoates Va-Vd and their base-catalyzed cyclization to 5-carboxy-2(1H)-pyrimidone derivatives VIa-VIc and 5-acyluracils VIIa-VIIc.